tetano
Editor, Senior Moderator
Int J Environ Res Public Health
. 2022 Mar 29;19(7):4039.
doi: 10.3390/ijerph19074039.
Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain
Jacobo Pardo-Seco[SUP] 1 2 3 [/SUP], Narmeen Mallah[SUP] 1 2 3 [/SUP], Luis Ricardo López-Pérez[SUP] 4 [/SUP], Juan Manuel González-Pérez[SUP] 4 [/SUP], Benigno Rosón[SUP] 4 [/SUP], María Teresa Otero-Barrós[SUP] 5 [/SUP], Carmen Durán-Parrondo[SUP] 5 [/SUP], Carmen Rodríguez-Tenreiro[SUP] 1 2 3 [/SUP], Irene Rivero-Calle[SUP] 1 2 3 6 [/SUP], Alberto Gómez-Carballa[SUP] 1 2 3 [/SUP], Antonio Salas[SUP] 1 3 7 8 [/SUP], Federico Martinón-Torres[SUP] 1 2 3 6 [/SUP]
Affiliations
Abstract
Investigating vaccine effectiveness (VE) in real-world conditions is crucial, especially its variation across different settings and populations. We undertook a test-negative control study in Galicia (Northwest Spain) to assess BNT162b2 effectiveness against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as well as COVID-19 associated hospitalization, intensive care unit (ICU) admission and mortality. A total of 44,401 positive and 817,025 negative SARS-CoV-2 test results belonging to adults were included. Adjusted odds ratios of vaccination and their 95% confidence interval (CI) were estimated using multivariate logistic-regression models. BNT162b2 showed high effectiveness in reducing SARS-CoV-2 infections in all age categories, reaching maximum VE ≥ 14 days after administering the second dose [18-64 years: VE = 92.9% (95%CI: 90.2-95.1); 65-79 years: VE = 85.8% (95%CI: 77.3-91.9), and ≥80 years: VE = 91.4% (95%CI: 87.9-94.1)]. BNT162b2 also demonstrated effectiveness in preventing COVID-19 hospitalization for all age categories, with VE more pronounced for those aged ≥80 years [VE = 60.0% (95%CI: 49.4-68.3)]. Moreover, there was a considerable reduction in ICU admission [VE = 88.0% (95%CI: 74.6-95.8)] and mortality [VE = 38.0% (95%CI: 15.9-55.4)] in the overall population. BNT162b2 showed substantial protection against SARS-CoV-2 infections and COVID-19 severity. Our findings would prove useful for systematic reviews and meta-analysis on COVID-19 VE.
Keywords: COVID-19; SARS-CoV-2; population study; vaccine effectiveness.
. 2022 Mar 29;19(7):4039.
doi: 10.3390/ijerph19074039.
Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain
Jacobo Pardo-Seco[SUP] 1 2 3 [/SUP], Narmeen Mallah[SUP] 1 2 3 [/SUP], Luis Ricardo López-Pérez[SUP] 4 [/SUP], Juan Manuel González-Pérez[SUP] 4 [/SUP], Benigno Rosón[SUP] 4 [/SUP], María Teresa Otero-Barrós[SUP] 5 [/SUP], Carmen Durán-Parrondo[SUP] 5 [/SUP], Carmen Rodríguez-Tenreiro[SUP] 1 2 3 [/SUP], Irene Rivero-Calle[SUP] 1 2 3 6 [/SUP], Alberto Gómez-Carballa[SUP] 1 2 3 [/SUP], Antonio Salas[SUP] 1 3 7 8 [/SUP], Federico Martinón-Torres[SUP] 1 2 3 6 [/SUP]
Affiliations
- PMID: 35409724
- DOI: 10.3390/ijerph19074039
Abstract
Investigating vaccine effectiveness (VE) in real-world conditions is crucial, especially its variation across different settings and populations. We undertook a test-negative control study in Galicia (Northwest Spain) to assess BNT162b2 effectiveness against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as well as COVID-19 associated hospitalization, intensive care unit (ICU) admission and mortality. A total of 44,401 positive and 817,025 negative SARS-CoV-2 test results belonging to adults were included. Adjusted odds ratios of vaccination and their 95% confidence interval (CI) were estimated using multivariate logistic-regression models. BNT162b2 showed high effectiveness in reducing SARS-CoV-2 infections in all age categories, reaching maximum VE ≥ 14 days after administering the second dose [18-64 years: VE = 92.9% (95%CI: 90.2-95.1); 65-79 years: VE = 85.8% (95%CI: 77.3-91.9), and ≥80 years: VE = 91.4% (95%CI: 87.9-94.1)]. BNT162b2 also demonstrated effectiveness in preventing COVID-19 hospitalization for all age categories, with VE more pronounced for those aged ≥80 years [VE = 60.0% (95%CI: 49.4-68.3)]. Moreover, there was a considerable reduction in ICU admission [VE = 88.0% (95%CI: 74.6-95.8)] and mortality [VE = 38.0% (95%CI: 15.9-55.4)] in the overall population. BNT162b2 showed substantial protection against SARS-CoV-2 infections and COVID-19 severity. Our findings would prove useful for systematic reviews and meta-analysis on COVID-19 VE.
Keywords: COVID-19; SARS-CoV-2; population study; vaccine effectiveness.